CTRI/2018/04/013464已完成3 期
A Prospective, Randomized, Double-blind, Double dummy, Multi Centre, Comparative Phase III Clinical Trial to Evaluate the Efficacy and Safety of Ivabradine Prolonged Release Tablets in Patients with Stable Chronic Heart Failure with Systolic Dysfunction
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 入组人数
- 180
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •1.Male and female between 18 to 70 years (both inclusive)
- •2.Currently receiving stable dose of Ivabradine IR 5 mg /7.5 mg BID since >= 1 month for stable chronic HF with systolic dysfunction
- •3.Concurrently receiving standard care for stable CHF (as per recommendation 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic HF)8
- •4.Documented stable chronic CHF of NYHA Class II to III >= 6 weeks at the time of screening
- •5.Sinus rhythm with clinically stable HR >50 bpm (both inclusive) as assessed automatically by a standard 12-lead ECG
- •6.Documented LVEF <=40 % at screening
- •7.No physical limitation to ingest and retain oral medication
- •8.Willingness to participate in the study and provide written informed consent
排除标准
- •1.History of recent MI, coronary revascularization, stroke, or transient ischemic attack <= 3 months), or with a transplanted heart, implanted pacemaker, implantable cardioverter defibrillator, or cardiac resynchronization therapy
- •2.Scheduled for coronary revascularization, or likely to require surgery for valvular disease during the study period
- •3.Permanent atrial fibrillation or flutter or any other cardiac arrhythmias which may interfere with function of sinoatrial node
- •4.Sick sinus syndrome, sinoatrial block, congenital long QT or treated with QT prolonging medications, 2nd degree and complete atrioventricular block
- •5.Stroke or transient cerebral ischemia within previous <= 3 months prior at screening
- •6.Unstable or acute HF, unstable angina
- •7.Severe or uncontrolled hypertension (systolic BP [SBP] >= 190 mmHg or diastolic BP [DBP] >= 110 mmHg) uncontrolled hypotension (SBP <= 90 mmHg or DBP <= 50 mmHg)
- •8.History of frequent hypoglycemia within <=3 months at screening
- •9.Hospitalization for worsening HF (NYHA class II or higher) <= 3 months at screening
- •10.Any cardiac condition which does not justify the inclusion of the patient in the study as per investigator discretion (e.g. severe primary valvular disease, active myocarditis, congenital heart disease, peripartum cardiomyopathy, etc.)
- •11.Patient having the following laboratory results at screening:
- •a.Hemoglobin (Hb) men <11 g/dL, women <10 g/dL
- •b.ALT/AST levels >= 3 Ñ? ULN
- •c.eGFR <15 mL/min
- •12.Women who are, pregnant, nursing, or planning to become pregnant or who are of childbearing potential not willing to implement appropriate contraceptive measures or who are considering to stop appropriate use of contraception during the study period
- •13.Contraindication to Ivabradine or its excipients; or Ivabradine not recommended or known to be not effective, or requirement for a not recommended concomitant treatment (as per Procoralanï?¢Ivabradine prescribing information and SPC of Procoralan®)
- •14.History of psychiatric disorders which may interfere with patientâ??s ability to understand or complete requirements of the study
- •15.Any other illness or conditions that does not justify patientâ??s participation in the study as judged by the investigator (E.g. Alcohol abuse, chronic illness like memory loss, Alzheimerâ??s etc)
- •16.Is currently participating in any other clinical trial or has participated in any other clinical trial 3 months prior to screening
- •17.Not willing to comply with all aspects of the protocol
研究者
相似试验
尚未招募
不适用
A Clinical Study to compare the Effects of Cilnidipine 10 mg Tablet versus Amlodipine 10 mg Tablet in Patients of Newly Diagnosed Hypertension.CTRI/2022/04/042233Dr Amey Beedkar
进行中（未招募）
1 期
A Prospective, Randomized, Double-Blind, Double-Dummy, Parallel-Group, Multicenter, Event-Driven, Non-inferiority Study Comparing the Efficacy and Safety of Once Daily Oral Rivaroxaban (BAY 59-7939) With Adjusted-Dose Oral Warfarin for the Prevention of Stroke and Non-Central Nervous System Systemic Embolism in Subjects With Non-Valvular Atrial Fibrillation (39039039AFL3001)EUCTR2006-004595-13-GBBayer HealthCare AG14,000
进行中（未招募）
1 期
A Prospective, Randomized, Double-Blind, Double-Dummy, Parallel-Group, Multicenter, Event-Driven, Non-inferiority Study Comparing the Efficacy and Safety of Once Daily Oral Rivaroxaban (BAY 59-7939) With Adjusted-Dose Oral Warfarin for the Prevention of Stroke and Non-Central Nervous System Systemic Embolism in Subjects With Non-Valvular Atrial Fibrillation (39039039AFL3001)EUCTR2006-004595-13-BGBayer HealthCare AG14,000
进行中（未招募）
1 期
A Prospective, Randomized, Double-Blind, Double-Dummy, MulticenterStudy to Assess the Safety and Efficacy of Doripenem Compared WithImipenem in the Treatment of Subjects with Ventilator-Associated PneumoniaMedDRA version: 9.1Level: LLTClassification code 10065153Term: <Manually entered code. Term in E.1.1>Ventilator-Associated PneumoniaEUCTR2007-004646-33-FRJanssen-Cilag International NV
进行中（未招募）
1 期
A Prospective, Randomized, Double-Blind, Double-Dummy, Parallel-Group, Multicenter, Event-Driven, Non-inferiority Study Comparing the Efficacy and Safety of Once Daily Oral Rivaroxaban (BAY 59-7939) With Adjusted-Dose Oral Warfarin for the Prevention of Stroke and Non-Central Nervous System Systemic Embolism in Subjects With Non-Valvular Atrial Fibrillation (39039039AFL3001) Estudio Prospectivo, Aleatorizado, Doble ciego, con Doble Enmascaramiento, de Grupos Paralelos, Multicéntrico, Basado en Acontecimientos, de No Inferioridad para Comparar la Eficacia y Seguridad de Rivaroxaban (BAY 59-7939) oral una vez al día con Warfarina Oral en Dosis Ajustadas para la Prevención del Accidente Cerebro Vascular y la Embolia Sistémica Periférica en Sujetos con Fibrilación Auricular no ValvularPrevention of Stroke and Non-CNS Systemic Embolism in Non-Valvular Atrial Fibrillation Prevención del Accidente Cerebro Vascular y la Embolia Sistémica Periférica en Fibrilación Auricular no ValvularMedDRA version: 8.1 Level: LLT Classification code 10003658 Term: Atrial fibrillationEUCTR2006-004595-13-ESBayer HealthCare AG